The trial is anticipated to be conducted in around 15 sites in the US and South Korea. Credit: PublicDomainPictures from Pixabay.

Bridge Biotherapeutics has obtained authorisation from the US Food and Drug Administration (FDA) for commencing a first-in-human trial of BBT-207 to treat non-small cell lung cancer (NSCLC).

The proposed Phase l/ll trial will assess the safety, tolerability, pharmacokinetics (PK), pharmacodynamics (PD) and preliminary antitumor activity of BBT-207 in advanced NSCLC patients harbouring epidermal growth factor receptor (EGFR) mutation post EGFR tyrosine kinase inhibitor (TKI) treatment.

Go deeper with GlobalData

Premium Insights

The gold standard of business intelligence.

Find out more

Related Company Profiles

View all

It will be carried out in dose escalation, recommended Phase ll dose selection and dose expansion phases.

During the trial, BBT-207 will be given orally throughout a 21-day cycle in each phase.

The trial is set to enrol up to 92 patients. It is anticipated to be conducted in around 15 sites in the US and South Korea.

See Also:

In the dose escalation phase of a Phase la trial, Bridge expects to determine the recommended dose range (RDR) based on the toxicity/tolerability, efficacy, PK and PD profiles of BBT-207.

How well do you really know your competitors?

Access the most comprehensive Company Profiles on the market, powered by GlobalData. Save hours of research. Gain competitive edge.

Company Profile – free sample

Thank you!

Your download email will arrive shortly

Not ready to buy yet? Download a free sample

We are confident about the unique quality of our Company Profiles. However, we want you to make the most beneficial decision for your business, so we offer a free sample that you can download by submitting the below form

By GlobalData
Visit our Privacy Policy for more information about our services, how we may use, process and share your personal data, including information of your rights in respect of your personal data and how you can unsubscribe from future marketing communications. Our services are intended for corporate subscribers and you warrant that the email address submitted is your corporate email address.

The Phase la trial also intends to detect BBT-207’s safety and tolerability based on treatment-related adverse events (AEs) and others.

As part of a Phase lb study, Bridge will choose the recommended Phase ll dose (RP2D) on the basis of PK, PD, objective response rate (ORR), duration of response (DOR), and the overall safety profile.

During the dose expansion stage, Phase ll preliminary antitumor activity of BBT-207 will be examined based on RECIST Version 1.1. 

Bridge Biotherapeutics founder and CEO James Lee said: “We’re excited to initiate the clinical development of BBT-207 in order to address the unmet medical needs of NSCLC patients.

“With this approval, the company will continue to focus on developing novel treatment options for late-stage lung cancer patients suffering from third-generation EGFR TKI resistance.”